SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

The collaboration revenue from net sales of zurzuvae was $36.1 million for the full year 2024 and $13.8 million for the first ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...